{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(2)"],"submitter":["Syamprasad NP"],"pubmed_abstract":["<h4>Background & aims</h4>The mechanism behind the progressive pathological alteration in metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH)-associated hepatocellular carcinoma (HCC) is poorly understood. In the present study, we investigated the role of the polyol pathway enzyme AKR1B1 in metabolic switching associated with MASLD/MASH and in the progression of HCC.<h4>Methods</h4>AKR1B1 expression was estimated in the tissue and plasma of patients with MASLD/MASH, HCC, and HCC with diabetes mellitus. The role of AKR1B1 in metabolic switching <i>in vitro was</i> assessed through media conditioning, lentiviral transfection, and pharmacological probes. A proteomic and metabolomic approach was applied for the in-depth investigation of metabolic pathways. Pre"],"journal":["JHEP reports : innovation in hepatology"],"pagination":["100974"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10820337"],"repository":["biostudies-literature"],"pubmed_title":["AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma."],"pmcid":["PMC10820337"],"pubmed_authors":["Jain S","Jorvekar SB","Borkar RM","Syamprasad NP","Vaidya JR","Challa VS","Rajdev B","Kumar GJ","Panda SR","Shaik KM","Shantanu PA","Tripathi DM","Naidu VGM"],"additional_accession":[]},"is_claimable":false,"name":"AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.","description":"<h4>Background & aims</h4>The mechanism behind the progressive pathological alteration in metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH)-associated hepatocellular carcinoma (HCC) is poorly understood. In the present study, we investigated the role of the polyol pathway enzyme AKR1B1 in metabolic switching associated with MASLD/MASH and in the progression of HCC.<h4>Methods</h4>AKR1B1 expression was estimated in the tissue and plasma of patients with MASLD/MASH, HCC, and HCC with diabetes mellitus. The role of AKR1B1 in metabolic switching <i>in vitro was</i> assessed through media conditioning, lentiviral transfection, and pharmacological probes. A proteomic and metabolomic approach was applied for the in-depth investigation of metabolic pathways. Pre","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-04-04T09:17:33.278Z","creation":"2025-04-04T09:17:33.278Z"},"accession":"S-EPMC10820337","cross_references":{"pubmed":["38283757"],"doi":["10.1016/j.jhepr.2023.100974"]}}